Bone Biologics Reaches Major Preclinical Milestone In Regenerative Bone Material Development
This article was originally published in Clinica
Bone Biologics is poised to reach an important milestone in its long journey to develop its NELL-1 osteoinductive protein into a commercially viable product for spine surgery. The firm plans to start large animal studies in the second half of 2016.
Register for our free email digests: